Alglucerase

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a692001
ATC code	A16AB01 (WHO)
Pharmacokinetic data
Elimination half-life	3.6–10.4 min
Identifiers
IUPAC name Human beta-glucocerebrosidase
CAS Number	143003-46-7 Y
DrugBank	DB00088 Y
ChemSpider	none
UNII	27T56C7KK0
KEGG	D09675 Y
ChEMBL	ChEMBL1201633 N
Chemical and physical data
Formula	C2532H3854N672O711S16
Molar mass	55597.64 g·mol−1
NY (what is this?)  (verify)

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues.^[1]

Ceredase is the trade name of a citrate buffered solution of alglucerase that was manufactured by Genzyme Corporation from human placental tissue.^[1] It is given intravenously in the treatment of Type 1 Gaucher's disease. This was the first drug approved as an enzyme replacement therapy.^[1]

It was approved by the FDA in 1991.^[2] It has been withdrawn from the market^[3][4] due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture^[1] (see imiglucerase).

References

External links

• Ceredase page at Harvard's Gaucher Treatment Program

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

• v
• t
• e